| Identification | Back Directory | [Name]
1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropyl-2,2,3,3-d4-carbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]- | [CAS]
2143107-55-3 | [Synonyms]
Olaparib-d4-1
1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropyl-2,2,3,3-d4-carbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]- | [Molecular Formula]
C24H23FN4O3 | [MOL File]
2143107-55-3.mol | [Molecular Weight]
434.47 |
| Hazard Information | Back Directory | [Uses]
Olaparib-d4-1 (AZD2281-d4-1) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Menear KA, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91 DOI:10.1021/jm8001263
[3] Senra JM, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Mol Cancer Ther. 2011 Oct;10(10):1949-58. DOI:10.1158/1535-7163.MCT-11-0278
[4] Yasukawa M, et al. Synergetic Effects of PARP Inhibitor AZD2281 in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int J Mol Sci. 2016 Feb 24;17(3):272. DOI:10.3390/ijms17030272
[5] Bian X, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018 Jan 18;37(3):341-351. DOI:10.1038/onc.2017.326 |
|
|